Revance (RVNC) and Crown Laboratories amended their Amended and Restated Merger Agreement. Under the terms of the Second Amendment, which has been unanimously approved by the Revance Board of Directors, Revance’s stockholders will receive $3.65 per share of common stock, par value $0.001 per share in cash, representing 55c or 17% per share more than the prior offer price. Crown’s tender offer has been extended until one minute past 11:59 p.m., Eastern Time, on February 4, unless the tender offer is further extended or earlier terminated. The transaction is expected to close by February 6. The outside termination date for the A&R Merger Agreement remains February 7. Crown does not intend to extend the outside termination date of the A&R Merger Agreement.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVNC:
- Crown Laboratories extends tender offer to acquire Revance Therapeutics
- Class Action Filed Against Revance Therapeutics, Inc. (RVNC) – March 04, 2025 Deadline to Join – Contact Levi & Korsinsky LLP
- Disney to own 70% of Fubo, Trudeau to resign as party leader: Morning Buzz
- Teoxane announces proposal to acquire Revance for $3.60 per share in cash
- Revance price target lowered to $3 from $7 at Barclays
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue